For advanced and recurrent or refractory HNSCC, common treatment regimens after progression from 1st or 2nd line chemotherapy include targeted therapy or immunotherapy with a PD-1 or PD-L1 inhibitor, regardless of HPV status. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.